down arrow

Hims & Hers Health, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4330001060
USD
40.02
2.95 (7.96%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

37.7240.46

52 Week

23.9772.98
Valuation
Technical
Day's Volume

CASH

24.76 M

Shareholding (Mar 2025)

FII

9.92%

Held by 153 FIIs

DII

46.46%

Held by 61 DIIs

Promoter

5.09%

How big is Hims & Hers Health, Inc.?

22-Jun-2025

As of Jun 18, Hims & Hers Health, Inc. has a market capitalization of $13.26 billion, with net sales of $1.78 billion and a net profit of $164.39 million over the last four quarters. The company reported shareholder's funds of $476.72 million and total assets of $724.81 million as of Dec 24.

Market Cap: As of Jun 18, Hims & Hers Health, Inc. has a market capitalization of 13,259.78 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Hims & Hers Health, Inc. reported net sales of 1,784.36 million and a net profit of 164.39 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 476.72 million and total assets of 724.81 million.

Read More

What does Hims & Hers Health, Inc. do?

22-Jun-2025

Hims & Hers Health, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $586 million and a net profit of $49 million. Key metrics include a P/E ratio of 74.00 and a return on equity of 30.96%.

Overview: <BR>Hims & Hers Health, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 586 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 49 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 13,259.78 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 74.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.58 <BR>Return on Equity: 30.96% <BR>Price to Book: 24.14<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Hims & Hers Health, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Hims & Hers Health, Inc. shows a mildly bullish trend with mixed technical signals, outperforming the S&P 500 significantly year-to-date and over the past year.

As of 10 October 2025, the technical trend for Hims & Hers Health, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The Bollinger Bands show a bullish stance on the weekly and mildly bullish on the monthly. Daily moving averages are bullish, supporting a positive short-term outlook. However, the KST is mildly bearish weekly and bullish monthly, and the Dow Theory indicates no trend in both weekly and monthly views. <BR><BR>In terms of performance, the company has significantly outperformed the S&P 500 over the longer terms, with a year-to-date return of 126.34% compared to the S&P 500's 11.41%, and a one-year return of 192.83% against 13.36%. Overall, the current technical stance is mildly bullish, with strength derived from daily moving averages and the monthly MACD.

Read More

Is Hims & Hers Health, Inc. overvalued or undervalued?

28-Oct-2025

As of October 24, 2025, Hims & Hers Health, Inc. is fairly valued with a P/E ratio of 74 and strong profitability metrics, having outperformed the S&P 500 with a 126.67% return over the past year.

As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a PEG ratio of 0.01, indicating potential growth relative to its price.<BR><BR>In comparison to peers, Hims & Hers has a P/E ratio that is higher than Addus HomeCare Corp. at 22.05 and significantly higher than Guardant Health, Inc., which has a negative P/E of -17.69. Despite the high valuation ratios, the company's strong ROCE of 50.18% and ROE of 30.96% suggest robust profitability. Over the past year, Hims & Hers has outperformed the S&P 500 with a return of 126.67% compared to the index's 16.90%, reinforcing its favorable valuation outlook.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 6.19%

  • The company has been able to generate a Return on Equity (avg) of 6.19% signifying low profitability per unit of shareholders funds
2

The company has declared Positive results for the last 13 consecutive quarters

3

With ROE of 30.96%, it has a fair valuation with a 22.96 Price to Book Value

4

Consistent Returns over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 11,220 Million (Small Cap)

stock-summary
P/E

74.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.31

stock-summary
Return on Equity

36.41%

stock-summary
Price to Book

19.94

Revenue and Profits:
Net Sales:
545 Million
(Quarterly Results - Jun 2025)
Net Profit:
43 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.82%
0%
-16.82%
6 Months
-25.35%
0%
-25.35%
1 Year
17.98%
0%
17.98%
2 Years
350.17%
0%
350.17%
3 Years
505.45%
0%
505.45%
4 Years
580.61%
0%
580.61%
5 Years
267.16%
0%
267.16%

Hims & Hers Health, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Hims & Hers Health, Inc. overvalued or undervalued?

As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a PEG ratio of 0.01, indicating potential growth relative to its price. In comparison to peers, Hims & Hers has a P/E ratio that is higher than Addus HomeCare Corp. at 22.05 and significantly higher than Guardant Health, Inc., which has a negative P/E of -17.69. Despite the high valuation ratios, the company's strong ROCE of 50.18% and ROE of 30.96% suggest robust profitability. Over the past year, Hims & Hers has outperformed the S&P 500 with a return of 126.67% compared to the index's 16.90%, reinforcing its favorable valuation outlook....

Read More
Hims & Hers Health, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

Hims & Hers Health, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

Hims & Hers Health, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 74 and a price-to-book value of 22.96. The company boasts a strong return on capital employed at 50.18% and a year-to-date return of 101.74%, amid significant stock volatility.

Read More

Is Hims & Hers Health, Inc. overvalued or undervalued?

As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 74, a Price to Book Value of 22.96, and an EV to EBITDA of 89.10. In comparison, Guardant Health, Inc. has a P/E of -17.69 and an EV to EBITDA of -19.11, while Addus HomeCare Corp. shows a fair valuation with a P/E of 22.05 and an EV to EBITDA of 15.27. Despite recent underperformance against the S&P 500 over the past week and month, Hims & Hers has demonstrated impressive year-to-date and one-year returns of 101.74% and 126.67%, respectively, significantly outpacing the index. This strong performance, combined with its fair valuation, suggests that the stock may have room for growth moving forward....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
357.97%
EBIT Growth (5y)
165.18%
EBIT to Interest (avg)
-19.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.58
Sales to Capital Employed (avg)
2.52
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
94.57%
ROCE (avg)
10.04%
ROE (avg)
6.19%
Valuation key factors
Factor
Value
P/E Ratio
74
Industry P/E
Price to Book Value
22.96
EV to EBIT
106.34
EV to EBITDA
89.10
EV to Capital Employed
53.36
EV to Sales
6.89
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
50.18%
ROE (Latest)
30.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 83 Schemes (38.46%)

Foreign Institutions

Held by 153 Foreign Institutions (9.92%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 72.62% vs 51.80% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 219.55% vs 284.72% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "544.80",
          "val2": "315.60",
          "chgp": "72.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "43.40",
          "val2": "15.30",
          "chgp": "183.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.20",
          "val2": "-0.60",
          "chgp": "-933.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "42.50",
          "val2": "13.30",
          "chgp": "219.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "60.50%",
          "val2": "36.90%",
          "chgp": "2.36%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 69.32% vs 65.50% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 636.17% vs 64.23% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,476.50",
          "val2": "872.00",
          "chgp": "69.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "85.10",
          "val2": "-23.90",
          "chgp": "456.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.10",
          "val2": "2.90",
          "chgp": "-310.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "126.00",
          "val2": "-23.50",
          "chgp": "636.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "46.10%",
          "val2": "-38.40%",
          "chgp": "8.45%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
544.80
315.60
72.62%
Operating Profit (PBDIT) excl Other Income
43.40
15.30
183.66%
Interest
0.00
0.00
Exceptional Items
-6.20
-0.60
-933.33%
Consolidate Net Profit
42.50
13.30
219.55%
Operating Profit Margin (Excl OI)
60.50%
36.90%
2.36%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 72.62% vs 51.80% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 219.55% vs 284.72% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,476.50
872.00
69.32%
Operating Profit (PBDIT) excl Other Income
85.10
-23.90
456.07%
Interest
0.00
0.00
Exceptional Items
-6.10
2.90
-310.34%
Consolidate Net Profit
126.00
-23.50
636.17%
Operating Profit Margin (Excl OI)
46.10%
-38.40%
8.45%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 69.32% vs 65.50% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 636.17% vs 64.23% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Hims & Hers Health, Inc. stock-summary
stock-summary
Hims & Hers Health, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."